Nabsys to Commercialize Electronic DNA Mapping Platform in 2014; Shows Data at AGBT | GenomeWeb

Following early access collaborations with academic research groups, Nabsys plans to start a beta-testing program for its single-molecule electronic DNA mapping platform by mid-year and to take orders for commercial systems in the second half of the year.

Two weeks ago at the Advances in Genome Biology and Technology conference in Marco Island, Fla., the company showed mapping data for viral, bacterial, and small eukaryotic genomes and demonstrated how its technology can help to correct de novo assemblies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.